Costs Up With Specialist As Predominant Provider of Care

This article originally appeared here.
Share this content:
Costs Up With Specialist As Predominant Provider of Care
Costs Up With Specialist As Predominant Provider of Care

TUESDAY, April 18, 2017 (HealthDay News) -- For older adults with multimorbidity, having a specialist as the predominant provider of care (PPC) is associated with higher spending and lower continuity of care, according to a study published online April 8 in the Journal of the American Geriatrics Society.

Julie P.W. Bynum, M.D., M.P.H., from the Dartmouth College Geisel School of Medicine in Lebanon, N.H., and colleagues conducted an observational study using propensity score matching involving beneficiaries aged 65 years and older with multimorbidity. Data were included for 3,934,942 beneficiaries with multimorbidity, of whom two-thirds had a primary care provider as their PPC.

The researchers found that, compared to those with a primary care PPC, individuals with a specialty PPC had more hospitalizations (40.3 more per 1,000) and higher spending ($1,781 more per beneficiary), although little difference was seen in mortality (0.2 percent higher) or preventable hospitalizations. The largest spending differences were seen for professional fees ($769 higher per beneficiary), inpatient stays ($572 higher per beneficiary), and outpatient facilities ($510 higher per beneficiary) (all P < 0.001). Individuals with a specialist PPC had lower continuity of care and saw more providers.

"Older adults with multimorbidity with a specialist as their main ambulatory care provider had higher spending and lower continuity of care than those whose PPC was in primary care but similar clinical outcomes," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Approves Admelog for Diabetes

FDA Approves Admelog for Diabetes

First drug approved as a follow-up product based on an abbreviated new process

High-Intensity Treadmill Exercise Feasible in Parkinson's Disease

High-Intensity Treadmill Exercise Feasible in Parkinson's Disease

Mean change in Unified Parkinson's Disease Rating Scale motor score lower for high-intensity exercise

is free, fast, and customized just for you!

Already a member?

Sign In Now »